At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BBH VanEck Biotech ETF
Not Yet Opened 10-29 16:00:00 EDT
256.90
+3.63
+1.43%
盘后256.90
+0.000.00%
19:30 EDT
High257.70Low254.18Vol11.30K
Open256.11D1 Closing253.27Amplitude1.39%
Mkt Cap520.61MTradable Cap520.61MTotal Shares2.03M
T/O2.89MT/O Rate0.56%Tradable Shares2.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vertex Minerals unlocks 24‑hour mining at Reward Gold Mine
TIPRANKS  ·  50 minutes ago
Vertex Minerals unlocks 24‑hour mining at Reward Gold Mine
Vertex Minerals Shareholders Back Comprehensive Option and Financing Package
TIPRANKS  ·  12:17
Vertex Minerals Shareholders Back Comprehensive Option and Financing Package
Gilead : RBC Raises Target Price to $131 from $126
THOMSON REUTERS  ·  12:03
Gilead : RBC Raises Target Price to $131 from $126
24H | Nasdaq Futures Fall 1.5%; Micron Slides 3%; Coinbase Sinks 5%; Amazon, AMD Drop over 6%; Reddit Plunges 18%; Intel Tumbles 23%
US Overnight  ·  08:14
24H | Nasdaq Futures Fall 1.5%; Micron Slides 3%; Coinbase Sinks 5%; Amazon, AMD Drop over 6%; Reddit Plunges 18%; Intel Tumbles 23%
Gilead Sciences Q3 Beats Expectations with Fastest Core Growth in Over a Decade, Raises Full-Year Sales Guidance but Faces 38% Medicare Price Cut on Biktarvy
Stock News  ·  06:50
Gilead Sciences Q3 Beats Expectations with Fastest Core Growth in Over a Decade, Raises Full-Year Sales Guidance but Faces 38% Medicare Price Cut on Biktarvy
Gilead Sciences, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  05:52
Gilead Sciences, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Gilead Hikes 2026 Sales Outlook, Says Medicare Cuts Biktarvy Price by 38% Starting in 2028
Reuters  ·  05:38
Gilead Hikes 2026 Sales Outlook, Says Medicare Cuts Biktarvy Price by 38% Starting in 2028
Gilead Sciences Management Commentary: HIV Growth Drives 16% Rise in Q3 2026 Base Business Sales
Reuters  ·  05:34
Gilead Sciences Management Commentary: HIV Growth Drives 16% Rise in Q3 2026 Base Business Sales
Afterhours Stock Roundup: Starbucks, Reddit, Pinterest, Intel
Dow Jones  ·  05:20
Afterhours Stock Roundup: Starbucks, Reddit, Pinterest, Intel
Gilead Says US Medicare Negotiated Price for Hiv Drug Biktarvy Set at $2,600 Per 30-Day Supply from Jan. 1, 2028 - Conf Call
THOMSON REUTERS  ·  05:13
Gilead Says US Medicare Negotiated Price for Hiv Drug Biktarvy Set at $2,600 Per 30-Day Supply from Jan. 1, 2028 - Conf Call
Gilead Says Price Represents Approximately 38% Discount to Medicare List Price - Conf Call
THOMSON REUTERS  ·  05:13
Gilead Says Price Represents Approximately 38% Discount to Medicare List Price - Conf Call
Gilead Sees About $1.5 Billion Hit in 2028 from Lower Biktarvy Prices in Medicare - Conf Call
THOMSON REUTERS  ·  05:13
Gilead Sees About $1.5 Billion Hit in 2028 from Lower Biktarvy Prices in Medicare - Conf Call
Gilead Boosted by HIV Prevention Demand
Dow Jones  ·  04:47
Gilead Boosted by HIV Prevention Demand
Gilead's 3Q EPS Squeezed by Rising R&D and SG&A Expenses
Dow Jones  ·  04:47
Gilead's 3Q EPS Squeezed by Rising R&D and SG&A Expenses
Gilead's COVID-19 Drug Veklury Slumps
Dow Jones  ·  04:47
Gilead's COVID-19 Drug Veklury Slumps
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  04:34
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  04:33
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Gilead Sciences Q3 2026 Net Income Falls 20% to $2.43 Billion; Q3 2026 Total Revenues Rise 7% to $8.3 Billion
Reuters  ·  04:14
Gilead Sciences Q3 2026 Net Income Falls 20% to $2.43 Billion; Q3 2026 Total Revenues Rise 7% to $8.3 Billion
Gilead Q3 Adjusted Earnings, Revenue Rise; Updates Guidance
MT Newswires Live  ·  04:13
Gilead Q3 Adjusted Earnings, Revenue Rise; Updates Guidance
Gilead Sciences Q3 Adjusted EPS Beats Estimates on HIV Growth; Raises Fy2026 Sales Outlook
Reuters  ·  04:11
Gilead Sciences Q3 Adjusted EPS Beats Estimates on HIV Growth; Raises Fy2026 Sales Outlook

Introduction

Company Name.
VanEck Biotech ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--